Physician profile
Renitra Jackson
NPI 1144399270
$1,097.32
in general payments reported to CMS, 2019-2025
16 companies · $856 in 2025
The $856 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $176 · 2024: $65.66 · 2025: $856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,097.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,097.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $236.47 | 2023-2025 | Mitraclip, Freestyle Libre 3 |
| Abbvie INC. | $210.30 | 2025 | |
| Novo Nordisk INC | $155.11 | 2025 | Wegovy, Ozempic |
| Lilly USA, LLC | $132.72 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $112.36 | 2025 | Repatha, Otezla, Evenity |
| Axsome Therapeutics, INC. | $43.59 | 2025 | Symbravo, Auvelity |
| Sanofi-Aventis U.S. LLC | $29.88 | 2024 | |
| Glaxosmithkline, LLC. | $29.38 | 2025 | Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $27.80 | 2025 | |
| Xeris Pharmaceuticals, INC. | $20.64 | 2025 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $18.34 | 2025 | Eliquis |
| Valinor Pharma, LLC | $18.31 | 2025 | Movantik |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.04 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.75 | 2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $15.71 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $13.92 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renitra Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.